Business Context and Reporting Period
Company: McKesson HBOC, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and nine months ended December 31, 2000.
Business Overview: The Company operates primarily through three segments: Health Care Supply Management (pharmaceutical and medical/surgical distribution), Health Care Information Technology (software, services, hardware), and iMcKesson (internet-based healthcare solutions). The period includes the formation of the iMcKesson segment and ongoing legal proceedings related to the 1999 acquisition of HBO & Company.
Key Financial Metrics
| Metric (in millions) | Q3 2000 | Q3 1999 | 9 Months 2000 | 9 Months 1999 |
|---|---|---|---|---|
| Revenues | $11,029.1 | $9,890.9 | $30,632.4 | $27,429.1 |
| Net Income | $1.7 | $166.8 | $127.2 | $296.2 |
| Diluted EPS (Total) | $0.01 | $0.58 | $0.45 | $1.04 |
| Operating Profit | $65.8 | $320.1 | $371.4 | $658.5 |
| Cash from Operations (9mo) | $81.6 | $166.6 | ||
| Cash & Equivalents (End) | ||||
| Total Assets | $11,436.8 | |||
| Long-Term Debt | $1,207.5 |
Note: Cash flow figures represent the nine-month period. Net debt-to-capital ratio was 18% as of December 31, 2000.
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased 11.5% in the quarter and 11.7% for the nine months, driven primarily by a 12.1% and 12.5% increase in the Health Care Supply Management segment.
- Profitability Decline: Net income collapsed to $1.7 million in Q3 2000 from $166.8 million in Q3 1999. This was primarily due to a $98.9 million impairment charge on equity investments in the iMcKesson segment, compared to $263.2 million in investment gains in the prior year.
- Segment Performance:
- Health Care Supply Management: Operating profit increased 45% in the quarter ($164.8M vs $113.3M) due to margin expansion and productivity improvements.
- iMcKesson: Reported an operating loss of $111.4 million in the quarter (vs. $248.9M profit in 1999) due to the investment impairment and restructuring costs.
- Health Care Information Technology: Revenues declined 10.6% and operating profit dropped to $12.4 million (from a loss of $42.1M in 1999, though prior year included significant charges).
- Liquidity: Cash and cash equivalents decreased to $333.2 million from $548.9 million at the start of the fiscal year, reflecting tax payments related to the prior year sale of the Water Products business and working capital increases.
Guidance, Risks, and Unusual Items
- Unusual Items:
- Investment Impairment: A $98.9 million pre-tax charge in Q3 2000 related to the decline in value of WebMD warrants and other equity investments held by iMcKesson.
- Restructuring: Charges of $3.8 million in the nine months ended Dec 31, 2000, for severance and facility closures across segments.
- Discontinued Operations: A $5.6 million after-tax loss in both the quarter and nine months, primarily an adjustment to the gain on the sale of the Water Products business.
- Legal Proceedings:
- Securities Litigation: Ongoing class action lawsuits regarding the 1999 HBOC acquisition and subsequent financial restatement. The Company filed a counterclaim against former HBOC shareholders alleging "unjust enrichment" due to inflated share exchange ratios.
- Antitrust: Pending appeals in federal and state court antitrust actions filed by retail pharmacies. The Company previously prevailed in the federal class action trial.
- Management Commentary: Management emphasizes that results excluding unusual items show underlying growth in the core distribution business. However, the iMcKesson segment faces headwinds from investment valuations and integration costs. No specific forward-looking financial guidance was provided in this text.
Investor Verification Checklist
- Investment Valuation: Verify the current fair value of remaining WebMD warrants and other equity investments held by iMcKesson to assess future impairment risks.
- Legal Exposure: Monitor the status of the securities litigation counterclaim against former HBOC shareholders and the potential for settlement or judgment in the antitrust appeals.
- Working Capital Trends: Review the significant increase in receivables ($507M increase) and inventories ($774M increase) to ensure they align with revenue growth and do not indicate collection or obsolescence issues.
- Segment Margins: Confirm the sustainability of the margin expansion in the Health Care Supply Management segment amidst competitive pricing pressures.
- Restructuring Costs: Track the remaining $15.0 million in restructuring reserves to estimate future cash outflows for severance and facility closures.